Levi Pederson

1.2k total citations
29 papers, 422 citations indexed

About

Levi Pederson is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Levi Pederson has authored 29 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 19 papers in Pathology and Forensic Medicine and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Levi Pederson's work include Colorectal Cancer Treatments and Studies (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Genetic factors in colorectal cancer (6 papers). Levi Pederson is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Genetic factors in colorectal cancer (6 papers). Levi Pederson collaborates with scholars based in United States, Italy and France. Levi Pederson's co-authors include Thomas E. Witzig, Philip J. Atherton, Qian Shi, Aimery de Gramont, Rachel Kerr, Julien Taı̈eb, Thierry André, Greg Yothers, Steven R. Alberts and Sara Lonardi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Levi Pederson

25 papers receiving 417 citations

Peers

Countries citing papers authored by Levi Pederson

Since Specialization

Citations

This map shows the geographic impact of Levi Pederson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Levi Pederson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Levi Pederson more than expected).

Fields of papers citing papers by Levi Pederson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Levi Pederson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Levi Pederson. The network helps show where Levi Pederson may publish in the future.

Co-authorship network of co-authors of Levi Pederson

This figure shows the co-authorship network connecting the top 25 collaborators of Levi Pederson. A scholar is included among the top collaborators of Levi Pederson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Levi Pederson. Levi Pederson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. 2025 ·Journal of Clinical Oncology ·Jonathan A. Nowak, Qian Shi, Tyler S. Twombly, Levi Pederson, (unknown), Juha P. Väyrynen, Melissa Zhao, Yasutoshi Takashima, Ardaman Shergill, Pankaj Kumar, Félix Couture, (unknown), Smitha Krishnamurthi, Benjamin Tan, Eileen M. O’Reilly, Anthony F. Shields, Shuji Ogino, Alexey Aleshin, Jeffrey A. Meyerhardt	2
2	Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP). 2025 ·Journal of Clinical Oncology ·Qian Shi, George J. Chang, Levi Pederson, Elliot A. Asare, Zhaohui Jin, Romain Cohen, Jeffrey A. Meyerhardt, Thierry André, Jeanne Tie, Jesse G. Dixon, Bryan E. Palis, Karla V. Ballman, Greg Yothers, (unknown), Steven R. Alberts, Chanjuan Shi, M. Kay Washington, Julien Taı̈eb, (unknown), Richard M. Goldberg	0
3	Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma 2024 ·Blood Advances ·Sarah C. Rutherford, Jun Yin, Levi Pederson, Kristie A. Blum, Peter Martin, Sin‐Ho Jung, Barbara Grant, Cara A. Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra J. Mandrekar, John P. Leonard	2
4	Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database 2024 ·British Journal of Cancer ·Christos S. Karapetis, (unknown), Michael J. Sorich, Levi Pederson, Eric Van Cutsem, Tim Maughan, J.-Y. Douillard, Chris J. O’Callaghan, (unknown), Carsten Bokemeyer, Alberto Sobrero, Chiara Cremolini, Benoist Chibaudel, John Zalcberg, Richard Adams, Marc Buyse, Marc Peeters, Takayuki Yoshino, Aimery de Gramont, Qian Shi	2
5	Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701. 2024 ·Journal of Clinical Oncology ·Jeremy S. Abramson, Susan M. Geyer, Levi Pederson, (unknown), Eric D. Hsi, Richard F. Little, Steven D. Gore, Daniel J. Landsburg, (unknown), Brad S. Kahl, Neha Mehta–Shah, Shira Dinner, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard	5
6	Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials 2023 ·Annals of Oncology ·Julien Taı̈eb, Frank A. Sinicrope, Levi Pederson, Sara Lonardi, Steven R. Alberts, Thomas J. George, Greg Yothers, Eric Van Cutsem, Leonard B. Saltz, Shuji Ogino, Rachel Kerr, Takayuki Yoshino, Richard M. Goldberg, Thierry André, Pierre Laurent‐Puig, Qian Shi	17
7	553O Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials 2023 ·Annals of Oncology ·Julien Taı̈eb, Levi Pederson, Frank A. Sinicrope, Sara Lonardi, Steven R. Alberts, Thomas J. George, Leonard B. Saltz, Greg Yothers, Richard M. Goldberg, Rachel Kerr, Takayuki Yoshino, Eric Van Cutsem, Shuji Ogino, Thierry André, Pierre Laurent‐Puig, Qian Shi	2
8	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts 2022 ·Blood Cancer Journal ·(unknown), Levi Pederson, Betsy LaPlant, Raphael Mwangi, Matthew J. Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew L. Feldman, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski	5
9	Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression 2022 ·Journal for ImmunoTherapy of Cancer ·N. Nora Bennani, Hyo Jin Kim, Levi Pederson, Pamela J. Atherton, Ivana N. Micallef, Gita Thanarajasingam, Grzegorz S. Nowakowski, Thomas E. Witzig, Andrew L. Feldman, Stephen M. Ansell	46
10	Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA 2020 ·JNCI Journal of the National Cancer Institute ·Pat Gulhati, Jun Yin, Levi Pederson, Hans‐Joachim Schmoll, Paulo M. Hoff, Jean‐Yves Douillard, J. Randolph Hecht, Christophe Tournigand, (unknown), Benoist Chibaudel, Aimery de Gramont, Qian Shi, Michael J. Overman	24
11	Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database 2020 ·Annals of Oncology ·Mohamed E. Salem, Jun Yin, Richard M. Goldberg, Levi Pederson, Norman Wolmark, Steven R. Alberts, Julien Taı̈eb, J. L. Marshall, Sara Lonardi, Takayuki Yoshino, Rachel Kerr, Greg Yothers, Axel Grothey, Thierry André, Aimery de Gramont, Qian Shi	17
12	Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database. 2020 ·Journal of Clinical Oncology ·Jun Yin, Romain Cohen, Zhaohui Jin, Heshan Liu, Levi Pederson, Richard Adams, Tim Maughan, Alan P. Venook, Eric Van Cutsem, Chiara Cremolini, (unknown), Michel Seymour, Carsten Bokemeyer, Eduardo Díaz‐Rubio, Harpreet Wasan, Volker Heinemann, Aimery de Gramont, Qian Shi, Heinz‐Josef Lenz	2
13	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma 2019 ·Blood ·N. Nora Bennani, Levi Pederson, Pamela J. Atherton, Ivana N. Micallef, Joseph P. Colgan, Gita Thanarajasingam, Grzegorz S. Nowakowski, Thomas E. Witzig, Andrew L. Feldman, Stephen M. Ansell	27
14	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies 2019 ·Annals of Oncology ·Julien Taı̈eb, Qian Shi, Levi Pederson, Steven R. Alberts, Norman Wolmark, Eric Van Cutsem, Aimery de Gramont, Rachel Kerr, Axel Grothey, Sara Lonardi, Takayuki Yoshino, Greg Yothers, Frank A. Sinicrope, Aziz Zaanan, Thierry André	98
15	N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2) 2019 ·Mayo Clinic Proceedings ·Terence T. Sio, (unknown), Paul J. Novotny, Samir H. Patel, Jean-Claude M. Rwigema, Levi Pederson, L.A. McGee, Mauricio E. Gamez, Grant R. Seeger, James A. Martenson, (unknown), (unknown), Yolanda I. Garces, Robert L. Foote, Robert C. Miller, Michele Y. Halyard	8
16	Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial 2018 ·International Journal of Radiation OncologyBiologyPhysics ·Terence T. Sio, Philip J. Atherton, Levi Pederson, (unknown), Robert W. Mutter, Yolanda I. Garces, J. Daniel, James L. Leenstra, Jean-Claude M. Rwigema, Shaker R. Dakhil, James D. Bearden, (unknown), Apar Kishor Ganti, Steven E. Schild, Robert C. Miller	14
17	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies 2018 ·Blood Cancer Journal ·Ayed O. Ayed, Annalisa Chiappella, Levi Pederson, Betsy LaPlant, Angela Giovanna Congiu, Gianluca Gaïdano, Michele Spina, Alessandro Re, Federica Cavallo, Gerardo Musuraca, William R. Macon, Thomas E. Witzig, Umberto Vitolo, Grzegorz S. Nowakowski	16
18	Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer. 2018 ·Journal of Clinical Oncology ·Pat Gulhati, Jun Yin, Levi Pederson, Hans‐Joachim Schmoll, Paulo M. Hoff, Jean‐Yves Douillard, J. Randolph Hecht, Christophe Tournigand, (unknown), Benoist Chibaudel, Aimery de Gramont, Qian Shi, Michael J. Overman	4
19	Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database. 2017 ·Journal of Clinical Oncology ·Alexis D. Leal, Fang‐Shu Ou, Aimery de Gramont, Levi Pederson, Alberto F. Sobrero, Marc Peeters, Dirk Arnold, Henry C. Pitot, Mace L. Rothenberg, Bruce J. Giantonio, Eric Van Cutsem, Daniel J. Sargent, Axel Grothey	0
20	Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992) 2016 ·Clinical Trials ·Philip J. Atherton, Kelli N. Burger, Levi Pederson, (unknown), Jeff A. Sloan	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact